Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
  Pharmaceutical Technology Europe E-Alert
 

06 August 2010

IN THIS ISSUE
PTE Digital August issue
EGA interview
Biosimilars not compelling
Biosimilars market
 
Biosimilars: too steep a mountain to climb?
Although there is a clear gap in the market for biosimilars, such products face a number of complex development hurdles and regulatory issues. PTE spoke with industry experts to find out how these challenges are being overcome and whether biosimilars represent a cost-effective investment. More...
 
Interview with the European Generic Medicines Association
One of Europe’s key stakeholders in biosimilar medicines explains the current environment for biosimilars and how Europe is increasing access to them. More...
 
True biosimilars do not offer a compelling business case
Why improving upon a biosimilar to create a ‘biosuperior’ could be a key strategy in the biopharmaceutical marketplace. More...
 
The biosimilars market today and tomorrow
Forecasting biosimilar sales is complex and although estimates vary it is clear that there is approximately a $50 billion potential for these medicines. More...
 

Latest blog posts
Protection from patent dependence
Actos cashes in on Avandia safety concerns
Sanofi aventis unhappy about generic Lovenox approval
More blog posts

Latest articles
Is your packaging line operating to full capacity?
The new EMA bioequivalence guideline: key considerations
Sterile production according to the new EU GMP annex 1: a focus on capping
More latest articles

Upcoming events
Charles Rivers Annual Biotech Symposium (13–15 September | USA)
DigiPharm Europe 2010 (28 September–1 October | UK)
Biobusiness Network (29–30 September | Switzerland)
More events


Survey
What is your main concern regarding the outsourcing of various services to emerging countries?
  Safety and quality issues  43%
  Lack of regulation 20%
  Job losses in the West 15%
  The distance 4%
  I have no concerns 18%

This week we would like to know...

Do you agree with the US Federal Trade Commission that pay-to-delay deals are anticompetitive?
Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone
numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Advanstar House, Park West, Sealand Road, Chester, CH1 4RN United Kingdom